 |
 Previous Article | Next Article 
Journal of Neuroscience, Vol 3, 1607-1619, Copyright © 1983 by Society for Neuroscience
Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons
LA Chiodo and BS Bunney
Extracellular single unit recording techniques were used to study the
effects of both acute and repeated oral neuroleptic administration on the
in vivo activity of rat A9 and A10 dopaminergic (DA) neurons. All
antipsychotic drugs examined acutely (haloperidol, l-sulpiride,
chlorpromazine, and clozapine) increased the number of spontaneously firing
DA neurons in both A9 and A10 compared to controls. Repeated (21 day)
treatment with haloperidol, l-sulpiride, and chlorpromazine (antipsychotic
drugs which can cause extrapyramidal side effects) markedly reduced the
number of active DA cells below control levels in both regions. The
"silent" DA neurons were in an apparent state of tonic depolarization
inactivation since they could be induced to discharge by the
microiontophoretic application of the inhibitory neurotransmitter
gamma-aminobutyric acid, but not the excitatory amino acid glutamate. The
depolarization inactivation observed may be specific for antipsychotic
drugs since a non-neuroleptic phenothiazine (promethazine), the inactive
isomer of sulpiride (d-sulpiride), and a tricyclic antidepressant
(desmethylimipramine) neither increased DA activity when given acutely nor
induced depolarization inactivation when administered repeatedly. In
contrast to the other drugs tested, repeated treatment with clozapine (an
effective antipsychotic drug which does not produce extrapyramidal side
effects) resulted in the depolarization inactivation of A10 neurons but not
A9 cells. These data suggest that neuroleptics which can induce
extrapyramidal side effects produce depolarization inactivation of both A9
and A10 neurons whereas antipsychotic drugs which lack this property
inactivate only A10 neurons. It is suggested that the time-dependent
development of A9 DA neuron inactivation induced by repeated neuroleptic
treatment may provide a mechanism for understanding the delayed onset of
extrapyramidal side effects often observed with these drugs.
This article has been cited by other articles:
|
|
|
|
 
K. Rasmussen, M.-A. Hsu, S. Noone, B. G. Johnson, L. K. Thompson, and S. K. Hemrick-Luecke
The Orexin-1 Antagonist SB-334867 Blocks Antipsychotic Treatment Emergent Catalepsy: Implications for the Treatment of Extrapyramidal Symptoms
Schizophr Bull,
November 1, 2007;
33(6):
1291 - 1297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gao, C.-L. Liu, S. Yang, G.-Z. Jin, B. S. Bunney, and W.-X. Shi
Functional Coupling between the Prefrontal Cortex and Dopamine Neurons in the Ventral Tegmental Area
J. Neurosci.,
May 16, 2007;
27(20):
5414 - 5421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rasmussen, M. J. Benvenga, F. P. Bymaster, D. O. Calligaro, I. R. Cohen, J. F. Falcone, S. K. Hemrick-Luecke, F. M. Martin, N. A. Moore, L. K. Nisenbaum, et al.
Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine
J. Pharmacol. Exp. Ther.,
December 1, 2005;
315(3):
1265 - 1277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-X. Shi
Slow Oscillatory Firing: A Major Firing Pattern of Dopamine Neurons in the Ventral Tegmental Area
J Neurophysiol,
November 1, 2005;
94(5):
3516 - 3522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tavakoli-Nezhad and D. K. Pitts
Postnatal Inorganic Lead Exposure Reduces Midbrain Dopaminergic Impulse Flow and Decreases Dopamine D1 Receptor Sensitivity in Nucleus Accumbens Neurons
J. Pharmacol. Exp. Ther.,
March 1, 2005;
312(3):
1280 - 1288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sarter, C. L Nelson, and J. P Bruno
Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia
Schizophr Bull,
January 1, 2005;
31(1):
117 - 138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Paquet, J. P. Soucy, E. Stip, M. Levesque, A. Elie, and M. A. Bedard
Comparison Between Olanzapine and Haloperidol on Procedural Learning and the Relationship With Striatal D2 Receptor Occupancy in Schizophrenia
J Neuropsychiatry Clin Neurosci,
February 1, 2004;
16(1):
47 - 56.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Agid, S. Kapur, T. Arenovich, and R. B. Zipursky
Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected
Arch Gen Psychiatry,
December 1, 2003;
60(12):
1228 - 1235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hahn, T. E. Tse, and E. S. Levitan
Long-Term K+ Channel-Mediated Dampening of Dopamine Neuron Excitability by the Antipsychotic Drug Haloperidol
J. Neurosci.,
November 26, 2003;
23(34):
10859 - 10866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.-Y. Shen
Ethanol Withdrawal Reduces the Number of Spontaneously Active Ventral Tegmental Area Dopamine Neurons in Conscious Animals
J. Pharmacol. Exp. Ther.,
November 1, 2003;
307(2):
566 - 572.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. SHIM
Action of Atypical Antipsychotics
Am J Psychiatry,
January 1, 2002;
159(1):
154 - 154.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Floresco, C. L. Todd, and A. A. Grace
Glutamatergic Afferents from the Hippocampus to the Nucleus Accumbens Regulate Activity of Ventral Tegmental Area Dopamine Neurons
J. Neurosci.,
July 1, 2001;
21(13):
4915 - 4922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Lewis and P. O'Donnell
Ventral Tegmental Area Afferents to the Prefrontal Cortex Maintain Membrane Potential 'Up' States in Pyramidal Neurons via D1 Dopamine Receptors
Cereb Cortex,
December 1, 2000;
10(12):
1168 - 1175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Ashby Jr., Y. Minabe, G. Stemp, J. J. Hagan, and D. N. Middlemiss
Acute and Chronic Administration of the Selective D3 Receptor Antagonist SB-277011-A Alters Activity of Midbrain Dopamine Neurons in Rats: An In Vivo Electrophysiological Study
J. Pharmacol. Exp. Ther.,
September 1, 2000;
294(3):
1166 - 1174.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. R. West and A. A. Grace
Striatal Nitric Oxide Signaling Regulates the Neuronal Activity of Midbrain Dopamine Neurons In Vivo
J Neurophysiol,
April 1, 2000;
83(4):
1796 - 1808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Boye and P.-P. Rompre
Behavioral Evidence of Depolarization Block of Dopamine Neurons after Chronic Treatment with Haloperidol and Clozapine
J. Neurosci.,
February 1, 2000;
20(3):
1229 - 1239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yamada, M. Harano, N. Annoh, and M. Tanaka
Dopamine D3 Receptors Modulate Evoked Dopamine Release from Slices of Rat Nucleus Accumbens Via Muscarinic Receptors, But Not from the Striatum
J. Pharmacol. Exp. Ther.,
December 1, 1999;
291(3):
994 - 998.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. Y. Lew, A. Garcia-Espana, K. Y. Lee, K. D. Carr, M. Goldstein, J. W. Haycock, and E. Meller
Increased Site-Specific Phosphorylation of Tyrosine Hydroxylase Accompanies Stimulation of Enzymatic Activity Induced by Cessation of Dopamine Neuronal Activity
Mol. Pharmacol.,
February 1, 1999;
55(2):
202 - 209.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. Di Giovanni, M. Di Mascio, V. Di Matteo, and E. Esposito
Effects of Acute and Repeated Administration of Amisulpride, a Dopamine D2/D3 Receptor Antagonist, on the Electrical Activity of Midbrain Dopaminergic Neurons
J. Pharmacol. Exp. Ther.,
October 1, 1998;
287(1):
51 - 57.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H. Moore, C. L. Todd, and A. A. Grace
Striatal Extracellular Dopamine Levels in Rats with Haloperidol-Induced Depolarization Block of Substantia Nigra Dopamine Neurons
J. Neurosci.,
July 1, 1998;
18(13):
5068 - 5077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Parada, L. Hernandez, M. P. De Parada, P. Rada, and E. Murzi
Selective Action of Acute Systemic Clozapine on Acetylcholine Release in the Rat Prefrontal Cortex by Reference to the Nucleus Accumbens and Striatum
J. Pharmacol. Exp. Ther.,
April 1, 1997;
281(1):
582 - 588.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. L. Miller and L. Ereshefsky
Schizophrenia: how should we look at it?
J Psychopharmacol,
January 1, 1997;
11(1):
21 - 23.
[PDF]
|
|
|
|
|
|
|
N. C. Moore, P. A. LeWitt, and S. Gershon
Reduction of dyskinesias and psychiatric disability with clozapine over different time courses
J Psychopharmacol,
January 1, 1992;
6(4):
514 - 518.
[Abstract]
[PDF]
|
|
|
|
